Navigation Links
Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
Date:3/18/2010

Tampa, FL (March 18, 2010) Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE technology for delivery of genes into cells.

Genes are the instructions that build cells. Defects in these genes cause disease, such as cancer. In order to understand how these genes work and their involvement in a disease process, researchers must study and modify them. The most common way to study gene function is to transfer the gene into cells. Transfection is the process of introducing foreign DNA, or genes, into cells. This fundamental process is critical in conducting medical research. However, low rates of transfection and high levels of cell death currently create bottlenecks.

Under the direction of Dr. Deepak Agrawal, Moffitt researchers have developed a proprietary technology that dramatically improves the functionality and performance of transfection technology. The patented Perforation Optimization and Repair Enhancement, or PORE, solves a number of immediate problems in the use of transfection by creating a higher level of efficiency and cell viability. This is particularly valuable for stem cells and primary cells that are the most medically relevant and the most difficult to transfect.

"I am very pleased that the PORE technology will be made available to researchers throughout the world," Agrawal said. "We believe PORE will fuel biological discovery by allowing more effective use of stem cells and primary cells for research, drug discovery and development of cell therapies."

"Proteacel's initial business activity will have Proteacel contracting to transfect specific hard to transfect cell lines with identified DNA," said Dr. Joseph Zendegui, president and chief operating officer of Proteacel. "Target customers for this service will be academic institutions and biotechnology companies in the biomedical research field. Using PORE as our technology base, we will expand our efforts into development and commercialization of drug discovery, cell differentiation assays."

"We are excited to see this technology move from the research labs here at Moffitt Cancer Center into the capable hands of Proteacel for the continuation of its development," said Ray Carpenter of Moffitt's Office of Technology Management and Commercialization. "Further, our office will remain focused on bridging entrepreneurs and Moffitt's faculty to cultivate local start-up company opportunities."

Under the terms of the License Agreement, Proteacel will pay Moffitt license fees, milestone payments and royalties on sales of PORE products and services.


'/>"/>

Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related biology news :

1. Could regulating intestinal inflammation prevent colon cancer?
2. Blocking cancer in its path: New cellular defect discovered
3. UAB oncologists: HPV vaccine protects from cancer recurrence
4. 2 at 1 stroke -- how cells protect themselves from cancer
5. 5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded
6. A golden bullet for cancer
7. Preventing gastric cancer with antibiotics
8. Berkeley scientists find new way to get physical in the fight against cancer
9. VAI researchers develop tool to help study prostate cancer
10. LSUHSC researcher finds first inherited prostate cancer genetic mutation in African-American men
11. Breast cancer drug fulvestrant appears more effective in the presence of CK8 and CK18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... , November 30, 2016 The global ... few players hold a dominant share in the overall ... Laboratories International, Inc., and Merck KGaA, held a lion,s ... Transparency Market Research observes that these companies are expected ... development products that are do not require rabbit pyrogen ...
(Date:11/30/2016)... VANCOUVER , Nov. 30, 2016 /PRNewswire/ -  Equicare ... coordination solutions, has been recognized as one of the ... 100, an annual international listing that distinguishes the top ... "We,ve pushed a great step forward this year continually ... growing our own customer base and team," says ...
(Date:11/30/2016)... -- Part of 5m$ Investment in Integrated Drug ... , ... today announced that it had successfully completed the expansion of ... increased the Screening Collection to over 400,000. The new compounds ... the company. This expansion, complemented by new robotics and compound ...
(Date:11/30/2016)... Triangle Park, NC (PRWEB) , ... November 30, ... ... development company engaged in the development of a new orally administered treatment for ... testing and neuroimaging results of a Phase 2a clinical trial of T3D-959 in ...
Breaking Biology Technology: